No Data
No Data
Huiyu Pharmaceutical (688553.SH): The total cost of RMB 3.1 million was repurchased 0.505%, and the joint stock company completed the repurchase
Gelonghui, May 23, 丨 Huiyu Pharmaceutical (688553.SH) announced that as of May 23, 2024, the company has completed the repurchase and has repurchased 2,139,878 shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 0.505% of the company's total share capital. The highest price of the repurchase transaction was 14.54 yuan/share, the lowest price was 12.57 yuan/share, and the total amount of capital paid was RMB 30.126.88 million (not including transaction fees).
China Grants Drug Registration for Huiyu Pharma's Two Injectables
China's medical products administrator granted a drug registration certificate to Sichuan Huiyu Pharmaceutical's (SHA:688553) cladribine and roxatidine hydrochloride acetate injections, according to a
Huiyu Pharmaceutical (688553.SH): Cladribine injections, roxatidine hydrochloride acetate for injections obtained drug registration certificates
Gelonghui, May 14 | Huiyu Pharmaceutical (688553.SH) announced that it has recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration. Drug name: cladribine injection, roxatidine hydrochloride acetate for injection. Cladribine is a synthetic antineoplastic drug. Rosatidine is a histamine H2 receptor antagonist.
Huiyu Pharmaceutical (688553.SH): No research and development projects using synthetic biology technology have entered the registration stage
Gelonghui, May 10 | Huiyu Pharmaceutical (688553.SH) said on an interactive platform that the company has not yet entered the registration stage for research and development projects applying synthetic biology technology, which will not have an impact on the company's performance at this stage and in the next two to three years.
Huiyu Pharmaceutical (688553.SH): 0.504% of shares have been repurchased
Gelonghui, May 6, 丨 Huiyu Pharmaceutical (688553.SH) announced that as of April 30, 2024, the company had repurchased 2,136,328 shares of the company through centralized bidding transactions, accounting for 0.504% of the company's total share capital. The highest purchase price was 14.54 yuan/share, the lowest price was 12.57 yuan/share, and the amount paid was RMB 29,962,782.49 (excluding transaction fees such as stamp duty and transaction commissions).
Huiyu Pharmaceutical (688553.SH): Benzenesulfonium atracurium injection obtained marketing approval in the UK
Zhitong Finance App News, Huiyu Pharmaceuticals (688553.SH) announced that Seacross Pharmaceuticals Ltd., a wholly-owned subsidiary of the company, recently received the approval and issuance of a marketing license from the UK Medicines and Health Products Administration (hereinafter referred to as the “UK Drug Administration”) for the company's product benzenesulfonate atracurium injection. According to reports, benzenesulfonium atracurium injection is suitable for surgical and other surgical treatment for adults and children aged 1 month and above, and can also be used in intensive care treatment for adults. This product can be used as a general anesthetic aid or as a sedative in ICU
No Data